Cover Image
市場調查報告書

難治型憂鬱症:開發中產品分析

Treatment Resistant Depression - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 302486
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
難治型憂鬱症:開發中產品分析 Treatment Resistant Depression - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 74 Pages
簡介

難治型憂鬱症(TRD)是服用抗憂鬱劑無效的重度憂鬱症。具有缺乏集中力、疲勞、失眠、暴食或食欲不振、持續性疼痛、頭痛、痙攣、消化器官異常等症狀。

本報告提供難治型憂鬱症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

難治型憂鬱症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

難治型憂鬱症:企業開發中的治療藥

難治型憂鬱症:大學/機關研究中的治療藥

難治型憂鬱症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

難治型憂鬱症:企業開發中的產品

難治型憂鬱症:大學/機關研究中的產品

難治型憂鬱症的治療藥的開發企業

  • Addex Therapeutics Ltd
  • Amorsa Therapeutics Inc.
  • Axsome Therapeutics, Inc.
  • Johnson & Johnson
  • 大塚集團

難治型憂鬱症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

難治型憂鬱症:最近的開發平台趨勢

難治型憂鬱症:暫停中的計劃

難治型憂鬱症:開發中止的產品

難治型憂鬱症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8591IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Treatment Resistant Depression - Pipeline Review, H2 2016, provides an overview of the Treatment Resistant Depression (Central Nervous System) pipeline landscape.

Treatment resistant depression (TRD) is an episode of major depressive disorder that does not respond to an antidepressant medication. Symptoms include difficulty concentrating, fatigue, insomnia, overeating or appetite loss and persistent aches or pains, headaches, cramps, or digestive problems. Treatment includes antidepressant from a different drug class, antipsychotic medication, electroconvulsive therapy (ECT) and vagus nerve stimulation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Treatment Resistant Depression - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Treatment Resistant Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Treatment Resistant Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Treatment Resistant Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 4 and 6 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Treatment Resistant Depression.

Treatment Resistant Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Treatment Resistant Depression (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Treatment Resistant Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Treatment Resistant Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Treatment Resistant Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Treatment Resistant Depression (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Treatment Resistant Depression (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Treatment Resistant Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Treatment Resistant Depression Overview
  • Therapeutics Development
    • Pipeline Products for Treatment Resistant Depression - Overview
    • Pipeline Products for Treatment Resistant Depression - Comparative Analysis
  • Treatment Resistant Depression - Therapeutics under Development by Companies
  • Treatment Resistant Depression - Therapeutics under Investigation by Universities/Institutes
  • Treatment Resistant Depression - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Treatment Resistant Depression - Products under Development by Companies
  • Treatment Resistant Depression - Products under Investigation by Universities/Institutes
  • Treatment Resistant Depression - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Amorsa Therapeutics Inc.
    • Avanir Pharmaceuticals, Inc.
    • Axsome Therapeutics Inc
    • Biohaven Pharmaceutical Holding Company Limited
    • Eli Lilly and Company
    • Evotec AG
    • Johnson & Johnson
    • Otsuka Holdings Co., Ltd.
    • Relmada Therapeutics, Inc.
    • Reviva Pharmaceuticals Inc.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Takeda Pharmaceutical Company Limited
  • Treatment Resistant Depression - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (bupropion hydrochloride + dextromethorphan hydrobromide) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (dextromethorphan + quinidine sulfate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMS-410 FA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMS-520 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVP-786 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CX-157 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSP-1200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • esketamine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EVT-100 Series - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-341495 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • REL-1017 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • riluzole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Insomnia, Obesity and Treatment Resistant Depression - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize mGluR2 for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-653 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VU-0431316 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Treatment Resistant Depression - Dormant Projects
  • Treatment Resistant Depression - Discontinued Products
  • Treatment Resistant Depression - Product Development Milestones
    • Featured News & Press Releases
      • Mar 17, 2016: Axsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant Depression
      • Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
      • Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Treatment Resistant Depression, H2 2016
  • Number of Products under Development for Treatment Resistant Depression - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Treatment Resistant Depression - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Treatment Resistant Depression - Pipeline by Amorsa Therapeutics Inc., H2 2016
  • Treatment Resistant Depression - Pipeline by Avanir Pharmaceuticals, Inc., H2 2016
  • Treatment Resistant Depression - Pipeline by Axsome Therapeutics Inc, H2 2016
  • Treatment Resistant Depression - Pipeline by Biohaven Pharmaceutical Holding Company Limited, H2 2016
  • Treatment Resistant Depression - Pipeline by Eli Lilly and Company, H2 2016
  • Treatment Resistant Depression - Pipeline by Evotec AG, H2 2016
  • Treatment Resistant Depression - Pipeline by Johnson & Johnson, H2 2016
  • Treatment Resistant Depression - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Treatment Resistant Depression - Pipeline by Relmada Therapeutics, Inc., H2 2016
  • Treatment Resistant Depression - Pipeline by Reviva Pharmaceuticals Inc., H2 2016
  • Treatment Resistant Depression - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Treatment Resistant Depression - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Treatment Resistant Depression - Dormant Projects, H2 2016
  • Treatment Resistant Depression - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Treatment Resistant Depression, H2 2016
  • Number of Products under Development for Treatment Resistant Depression - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top